-
1-Year DFS Reaches 93%! RC48-ADC Plus Radiotherapy Breaks the Adjuvant Treatment Dilemma for Cisplatin-Ineligible UTUC
During a recent academic session, Dr. Tao Zihao from Peking University First Hospital presented the preliminary results of a Phase II study evaluating the efficacy and safety of Disitamab Vedotin (RC48-ADC) in combination with radiotherapy for the adjuvant treatment of Upper Tract Urothelial Carcinoma (UTUC). This study provides a potential new therapeutic strategy for high-risk…
-
71.9% CR Rate at 3 Months: RC48 Combined with PD-1 Inhibitors Emerges as a Promising Bladder-Sparing Strategy for HR-NMIBC
At a recent academic symposium, Dr. Xuanjun Guo (Peking University First Hospital) presented data from a multicenter real-world study evaluating the efficacy and safety of Disitamab Vedotin (RC48), a humanized anti-HER2 antibody-drug conjugate (ADC), administered as monotherapy or in combination with PD-1 inhibitors for high-risk non-muscle-invasive bladder cancer (HR-NMIBC). This study provides critical real-world evidence…
-
EAU26 Afternoon Tea Dialogue | Prof. Jianming Guo’s Team: Disease-Specific AI Large Model Enables Precise Preoperative Assessment of Renal Cancer
The 41st Annual Congress of the European Association of Urology (EAU26) was held in London, UK, from March 13–16, 2026, serving as one of the most important global academic platforms in urology.
-
Voice of China at ASCO-GU | Prof. Haige Chen and Prof. Ruiyun Zhang: Renji Hospital’s Urothelial Carcinoma Team Showcases Multiple Studies on the International Stage, Advancing Bladder-Preserving Therapy and Liquid Biopsy
The 2026 ASCO Genitourinary Cancers Symposium (ASCO-GU) recently concluded successfully in San Francisco, USA. As one of the most influential global academic conferences in the field of genitourinary oncology, the meeting brings together the latest research advances and evolving clinical perspectives from around the world.
-
EAU26 Afternoon Tea Dialogue | Prof. Jianming Guo’s Team: Hormone Therapy Combined with Cytoreductive Surgery Offers a New Strategy for Oligometastatic Prostate Cancer
The 41st Annual Congress of the European Association of Urology (EAU26) was held in London, UK, from March 13–16, 2026, serving as one of the most influential academic platforms in global urology.
-
World Kidney Day 2026 | Prof. Lei Liu: Challenges and Strategies in Preventing and Managing Infections After Kidney Transplantation
For patients with end-stage kidney disease, kidney transplantation represents a life-changing treatment that can restore quality of life and offer a “second chance.” However, transplantation success is only the beginning of a long journey. Lifelong immunosuppressive therapy—while essential for preventing rejection—also exposes recipients to a significant risk: infection.
-
ASCO-GU Expert Insights | Prof. Darren Poon Interprets the BRCAAway Study: Median OS Reaches 68 Months with First-Line PARP Inhibitor Therapy in mCRPC
The concept of synthetic lethality, achieved through PARP inhibitors (PARPi), has ushered in the era of precision therapy for prostate cancer. Clinical studies evaluating PARPi either as monotherapy or in combination with next-generation androgen receptor pathway inhibitors (ARPI), such as PROfound and PROpel, have already produced landmark advances in the treatment of metastatic castration-resistant prostate…
-
ASCO GU On-Site Report | Prof. Xinan Sheng: A China-Developed Targeted–Immunotherapy Combination Opens a New Era of Bladder-Preserving Treatment for MIBC
The treatment landscape for muscle-invasive bladder cancer (MIBC) is undergoing profound transformation. Although cisplatin-based neoadjuvant chemotherapy remains the traditional standard of care, the pathological complete response (pCR) rate has long remained at approximately 30%–40%, and a substantial proportion of patients cannot receive cisplatin due to factors such as renal insufficiency. Consequently, more effective preoperative treatment…
Connecting Medical Expertise through Media